(1H,6H)-3-Aza-9-oxabicyclo<4.2.1>nonan | 69928-94-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧氮杂卓类
• 英文名称: (1H,6H)-3-Aza-9-oxabicyclo<4.2.1>nonan
• 英文别名: 9-Oxa-3-azabicyclo[4.2.1]nonane
• CAS: 69928-94-5
• 化学式: C₇H₁₃NO
• mdl: MFCD19223824
• 分子量: 127.186
• InChiKey: WWPSNCRLHCSSDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  苯乙酸 、 (1H,6H)-3-Aza-9-oxabicyclo<4.2.1>nonan 在 sodium tetrahydroborate 作用下， 以 苯 为溶剂， 反应 20.0h， 以45%的产率得到N-(2-Phenylethyl)-(1-αH,6-αH)-3-aza-9-oxabicyclo<4.2.1>nonan
  参考文献：
  名称：

  Synthese, Reaktionen 和 ZNS-Wirkungen 6,7-anellierter 8-Oxatropanderivate

  摘要：

  Die Butadienderivate 10a-c reagieren mit dem Oxabicyclooctenon 9 zu den cyclohexenanellierten Oxatropanen 11a-c。乙酰氧基衍生物 11b bzw。11c können in Cyclohexadienoder Benzol-Derivate 13 bzw。12 übergeführt werden。11a setzt sich mit HN3 zum tricyclischen Oxazep​​anon 14 um, das sich zum Oxazep​​an 15a reduzieren läßt; das Oximtosylat 16b 反应剂 mit Al(CH3)3/DIBALH zum Oxazep​​an 15c。苯并三氮卓 bzw。重氮甲烷 entstehen aus

  DOI：

  10.1002/ardp.19923250205
• 作为产物：
  描述：

  9-oxa-3-azabicyclo<4.2.1>nonan-4-one 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 (1H,6H)-3-Aza-9-oxabicyclo<4.2.1>nonan
  参考文献：
  名称：

  Synthese, Reaktionen 和 ZNS-Wirkungen 6,7-anellierter 8-Oxatropanderivate

  摘要：

  Die Butadienderivate 10a-c reagieren mit dem Oxabicyclooctenon 9 zu den cyclohexenanellierten Oxatropanen 11a-c。乙酰氧基衍生物 11b bzw。11c können in Cyclohexadienoder Benzol-Derivate 13 bzw。12 übergeführt werden。11a setzt sich mit HN3 zum tricyclischen Oxazep​​anon 14 um, das sich zum Oxazep​​an 15a reduzieren läßt; das Oximtosylat 16b 反应剂 mit Al(CH3)3/DIBALH zum Oxazep​​an 15c。苯并三氮卓 bzw。重氮甲烷 entstehen aus

  DOI：

  10.1002/ardp.19923250205

文献信息

• [EN] MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE<br/>[FR] MONOBACTAMES ET PROCÉDÉS DE SYNTHÈSE ET D'UTILISATION DE CES DERNIERS
  申请人：HARVARD COLLEGE

  公开号：WO2015103583A1

  公开（公告）日：2015-07-09

  Described herein are monobactam antibiotics of Formula (I), (Ι'), (II), and (II'), along with methods and intermediates for preparing these compounds. Pharmaceutical compositions and methods of treating infectious diseases using the monobactams are also provided.

  本文描述了单环内酰胺抗生素的化学式(I)、(Ι')、(II)和(II')，以及制备这些化合物的方法和中间体。还提供了使用单环内酰胺治疗传染病的药物组合物和方法。
• Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
  申请人：Nurix Therapeutics, Inc.

  公开号：US11530229B2

  公开（公告）日：2022-12-20

  Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.

  本发明公开了用于抑制泛素蛋白酶体途径中的 E3 酶 Cbl-b 的化合物、组合物和方法。这些化合物、组合物和方法可用于调节免疫系统，治疗免疫系统可调节的疾病，以及体内、体外或体外细胞的治疗。还公开了包含 Cbl-b 抑制剂和癌症疫苗的药物组合物，以及使用 Cbl-b 抑制剂和癌症疫苗治疗癌症的方法；以及包含 Cbl-b 抑制剂和溶瘤病毒的药物组合物，以及使用 Cbl-b 抑制剂和溶瘤病毒治疗癌症的方法。
• MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE
  申请人：PRESIDENT AND FELLOWS OF HARVARD COLLEGE

  公开号：US20160326157A1

  公开（公告）日：2016-11-10

  Described herein are monobactam antibiotics of Formula (I), (I′), (II), and (II′), along with methods and intermediates for preparing these compounds. Pharmaceutical compositions and methods of treating infectious diseases using the monobactams are also provided.
• CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF
  申请人：Nurix Therapeutics, Inc.

  公开号：US20210053986A1

  公开（公告）日：2021-02-25

  Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
• [EN] CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF<br/>[FR] COMPOSÉS CYANO-CYCLOBUTYLE POUR L'INHIBITION DE CBL-B ET LEURS UTILISATIONS
  申请人：NURIX THERAPEUTICS INC

  公开号：WO2020236654A1

  公开（公告）日：2020-11-26

  Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.